Cargando…
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481078/ https://www.ncbi.nlm.nih.gov/pubmed/32907817 http://dx.doi.org/10.1136/esmoopen-2020-000867 |
| _version_ | 1783580527412903936 |
|---|---|
| author | Ardini, Elena Siena, Salvatore |
| author_facet | Ardini, Elena Siena, Salvatore |
| author_sort | Ardini, Elena |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7481078 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74810782020-09-18 Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies Ardini, Elena Siena, Salvatore ESMO Open Editorial BMJ Publishing Group 2020-09-08 /pmc/articles/PMC7481078/ /pubmed/32907817 http://dx.doi.org/10.1136/esmoopen-2020-000867 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Editorial Ardini, Elena Siena, Salvatore Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title_full | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title_fullStr | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title_full_unstemmed | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title_short | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| title_sort | entrectinib approval by ema reinforces options for ros1 and tumour agnostic ntrk targeted cancer therapies |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481078/ https://www.ncbi.nlm.nih.gov/pubmed/32907817 http://dx.doi.org/10.1136/esmoopen-2020-000867 |
| work_keys_str_mv | AT ardinielena entrectinibapprovalbyemareinforcesoptionsforros1andtumouragnosticntrktargetedcancertherapies AT sienasalvatore entrectinibapprovalbyemareinforcesoptionsforros1andtumouragnosticntrktargetedcancertherapies |